ai3Bio Launches with $48 Million in Series A Funding to Reset the Immune System at Its Root
WATERTOWN, Mass.--(BUSINESS WIRE)--ai3Bio launches with $48M in Series A funding to reset the immune system at its root, advancing platforms targeting Th17 cells in vivo.